All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Arfolitixorin,Fluorouracil,Oxaliplatin
Therapeutic Area: Oncology Product Name: Arfox
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2021
Details:
The patent application that will be granted includes a dose regimen involving two or more injections of arfolitixorin in combination with 5-fluorouracil (5-FU).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Arfolitixorin,Fluorouracil,Oxaliplatin
Therapeutic Area: Oncology Product Name: Arfox
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 19, 2021
Details:
The iDSMB has recommended continuation of the global Phase III AGENT study with 440 patients, in accordance with the study design for the drug candidate, arfolitixorin. Isofol expects the top line results for the AGENT study to be available during H1 2022.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Melphalan Flufenamide,Dexamethasone,Daratumumab
Therapeutic Area: Oncology Product Name: Melflufen
Highest Development Status: Phase III Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2020
Details:
The phase 3 LIGHTHOUSE study is a randomized, open-label study in patients with relapsed refractory multiple myeloma who are refractory to an immunomodulatory agent and a proteasome inhibitor or who have had at least three prior lines of therapy, including these agents.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Arfolitixorin,Oxaliplatin,Fluorouracil
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 09, 2020
Details:
Isofol’s drug candidate, arfolitixorin, is evaluated for treatment of patients with first-line metastatic colorectal cancer (mCRC). The AGENT study is currently being conducted in the U.S., Canada, Europe, Australia and Japan at more than 90 clinics.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Arfolitixorin,Oxaliplatin,Fluorouracil
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: PALADIN LABS
Deal Size: $100.0 million Upfront Cash: $103.0 million
Deal Type: Licensing Agreement November 02, 2020
Details:
The license agreement is initially focused on the development and commercialization of arfolitixorin as first-line treatment for metastatic colorectal cancer (mCRC) patients in Japan, which is projected to be the second largest addressable patient market for arfolitixorin.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
